Recon: Peter Marks joins Eli Lilly to head infectious disease unit; AstraZeneca blood pressure drug hit main goal in Phase 3 trial

• Peter Marks, FDA vaccine regulator ousted by RFK Jr., joins Eli Lilly (STAT)
• Parents are flocking to natural and ‘clean medicine’ brands. Medical experts are worried (STAT)
• Acting CDC director calls for MMR vaccine to be broken up into three shots (STAT)
• J&J ordered to pay $966 million in talc cancer case after jury finds company liable (Reuters)
• Novo Nordisk cuts hit production line jobs at key US plant (Reuters)
• Inside Warning Letters: A Statistical Update (FDA Law Blog)
• Trump Opens Door to Talks GOP Has Resisted as Shutdown Extends (Bloomberg)
• White House memo says furloughed federal workers aren't entitled to back pay (Axios)

• With much to win (or lose), drugmakers and European officials bear down on major policy overhaul (STAT)
• Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing (MedTech Insight)
• Eli Lilly earmarks $1B to boost India manufacturing footprint (Endpoints)
• AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial (Reuters)
• Defining Unmet Medical Need: EU Debate Sparks Concern Over Innovation And Access (Pink Sheet)
• ‘Urgent Need’ To Scale Up Advice Slots Under EU HTA Regulation – EUCOPE (Pink Sheet)
• Novo Ex-CEO Jorgensen Gets New Job at Danish Health-Care Lobby (Bloomberg)
• Prosthetics maker Ottobock plans to raise $941 million in German IPO (Reuters)

• Drug developer MapLight eyes $704.3 million valuation in US IPO (Reuters)
• Soufflé Therapeutics, co-founded by Bob Langer, launches with $200M (Endpoints)
• Mark Alles’ biotech gets $96M for ADCs from UCLA lab (Endpoints)
• Lexeo eyes faster path to approval for Friedreich's ataxia gene therapy (Endpoints)
• Adicet reveals Phase 1 data for lupus therapy; Arcus’ ‘best-in-class’ kidney cancer drug (Endpoints)
• Biopharma makes little progress on gender diversity, as women make up 11% of CEO ranks (Endpoints)
• Biomea shares early Phase 2 diabetes data from repurposed cancer candidate (Endpoints)
• AeroRx closes $21M Series A in bid to capitalize on COPD momentum (Endpoints)
• Engineered Protein That Responds to Light Could Help Restore Sight (Bloomberg)

• How the FDA’s crackdown on cybersecurity affects medtech firms (MedTech Dive)
• How 4 medtech CEOs are using AI (MedTech Dive)
• AdvaMed Warns Of Challenges With Remote Devices While Noting Their Potential (MedTech Insight)
• Convatec plans $1B investment in R&D in the US and UK (MedTech Dive)

• AI is set to transform the way consumers shop for food (Food Dive)
• Tyson agrees to record $85M settlement in pork price-fixing lawsuit (Food Dive)

• They advised federal health agencies on the ethics and impact of scientific research. They’re no longer wanted (STAT)
• What RFK Jr. gets wrong about medical school and nutrition education (STAT)
• US health official calls for separating measles combination shots, pulls broad COVID vaccine support (Reuters)
• Gilead inks Biktarvy settlements with 3 generic drug makers (Fierce Pharma)
• TV drug ad spending picked up in September despite federal crackdown (Fierce Pharma)
• Massachusetts Effort to Offset Trump’s Research Cuts Stalls (Bloomberg)